$UPST has recently broken below where it opened at its IPO back in late 2020 at around $20. It will be interesting to see if it can break back above $20 or continues to drift downwards.
| PRISM Stock Indexes | Current Value | % Change (Daily) | % Change (Inception) | Most Active | Top % Gainers | Top % Losers |
|---|---|---|---|---|---|---|
| Cannabis | $79.10 | 5.6% | -20.9% | TLRY 21,727 | CLVR 12.957% | CVSI -4.595% |
| EV | $57.20 | 1.6% | -42.8% | NKLA 13,152 | NKLA 9.615% | TPGY 0% |
| Gene Therapy | $61.30 | 1.5% | -38.7% | BLUE 5,733 | BLUE 11.564% | BNTC -5% |
| MedDevices | $174.30 | -0.3% | 74.3% | ATRS 5,230 | VAPO 20% | CHFS 0% |
| MedDiagnostics | $88.10 | -0.7% | -11.9% | OPK 2,309 | NDRA 10% | OPGN -17.029% |
| Solar | $95.90 | 5.7% | -4.1% | HYSR 7,523 | SOL 16.703% | SIRC -3.813% |
| Uranium | $81.70 | -0.8% | -18.3% | UEC 8,842 | LEU 2.492% | URG -3.906% |
| Vaccines & Cell Therapy | $184.90 | 1.2% | 84.9% | SRNE 7,297 | VXRT 11.111% | APOP 0% |
| Web 3.0 | $28.00 | 2.7% | -72.0% | MARA 17,366 | DEFTF 15.2% | SNII 0% |
Lexaria Bioscience (Nasdaq): LEXX is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world’s biggest public health crises.
The global dementia drug market is projected to reach $32.3 billion by 2030 diabetes and the diabetes drug market is expected to reach $82.92 billion by 2027.
Lexaria recently demonstrated DehydraTECH-CBD exceptional safety and tolerability in a human hypertension study, along with statistically significant lowering of blood pressure over multiple weeks; something that previous studies by others have failed to evidence. Strong connections have been established between hypertension and dementia and diabetes.
The company’s patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream and has demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs and PDE5 inhibitors. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, an important factor in treating dementia.
We spoke to John Docherty, Lexaria’s President and Head of Research, to find out more.
$UPST has recently broken below where it opened at its IPO back in late 2020 at around $20. It will be interesting to see if it can break back above $20 or continues to drift downwards.
